Global Gene Therapy Market to Reach US$3.4 Billion by the Year 2027

New York, July 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Gene Therapy Industry" - https://www.reportlinker.com/p05817594/?utm_source=GNW
5 Million in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 19.5% over the period 2020-2027.Viral, one of the segments analyzed in the report, is projected to grow at a 19.7% CAGR to reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Viral segment is readjusted to a revised 17.6% CAGR for the next 7-year period. This segment currently accounts for a 11.1% share of the global Gene Therapy market.

The U.S. Accounts for Over 53.7% of Global Market Size in 2020, While China is Forecast to Grow at a 25.1% CAGR for the Period of 2020-2027

The Gene Therapy market in the U.S. is estimated at US$521.3 Million in the year 2020. The country currently accounts for a 53.71% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$107.9 Million in the year 2027 trailing a CAGR of 25.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.3% and 18.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.6% CAGR while Rest of European market (as defined in the study) will reach US$107.9 Million by the year 2027.

Select Competitors (Total 154 Featured)

• Abeona Therapeutics Inc.
• Adaptimmune Therapeutics Plc
• Advantagene, Inc.
• Adverum Biotechnologies, Inc
• Akcea Therapeutics
• Alnylam Pharmaceuticals, Inc.
• Amgen Inc
• Anchiano Therapeutics, Inc.
• AnGes, Inc.
• Applied Genetic Technologies Corporation
• Audentes Therapeutics, Inc.
• Biogen
• bluebird bio, Inc.
• Chiesi Farmaceutici S.p.A
• CRISPR Therapeutics AG
• Editas Medicine, Inc.
• Gilead Sciences, Inc.
• Intellia Therapeutics, Inc.
• Jazz Pharmaceuticals, plc.
• Juno Therapeutics, Inc
• Merck KGaA
• MolMed S.p.A.
• Novartis Gene Therapies
• Orchard Therapeutics plc
• REGENXBIO Inc.
• Sangamo Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Sibiono GeneTech Co. Ltd.
• Spark Therapeutics, Inc.
• uniQure N.V.
• Voyager Therapeutics

Read the full report: https://www.reportlinker.com/p05817594/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
A Prelude to Gene Therapy
Classification of Gene Therapies
COVID-19 Causes Gene Therapy Market to Buckle & Collapse
COVID-19 Impact on Different Aspects of Gene Therapy
Manufacturing & Delivery
Research & Clinical Development
Commercial Operations & Access
Managing Derailed Operations
Focus on Clinical Development Programs
Targeting Manufacturing & Delivery Strategies
Securing Supplies
Remote Working
Gene Therapy Set to Witness Rapid Growth Post COVID-19
By Vector Type
VIRAL VECTORS ACCOUNT FOR A MAJOR SHARE OF THE MARKET
Adeno-Associated Virus Vectors
Lentivirus
NON-VIRAL VECTORS TO WITNESS FASTER GROWTH
US and Europe Dominate the Gene Therapy Market
Oncology Represents the Largest Indication for Gene Therapy
Market Outlook
WORLD BRANDS

2. FOCUS ON SELECT PLAYERS
Recent Market Activity
Select Innovations

3. MARKET TRENDS & DRIVERS
Availability of Novel Therapies Drive Market Growth
Select Approved Gene Therapy Products
Adeno-associated Virus Vectors - A Leading Platform for Gene
Therapy
Lentiviral Vectors Witness Increasing Interest
Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy
EXHIBIT 1: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 2: Global Number of New Cancer Cases and Cancer-related
Deaths by Cancer Site for 2018
EXHIBIT 3: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018
Compelling Level of Technology & Innovation to Ignite Gene Therapy
Promising Gene Therapy Innovations for Treatment of Inherited
Retinal Diseases
Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic
Medicine
M&As Rampant in Gene Therapy Space
Gene Therapy Deals: 2018 and 2019
Emphasis on Formulating Robust Regulatory Framework
Strong Gene Therapy Pipeline
Gene Therapy: Phase III Clinical Trials
OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial
with CRISPR
Growing Funding for Gene Therapy Research
Market Issues & Challenges

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Gene Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 2: World Historic Review for Gene Therapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2017 through 2019 and % CAGR

Table 3: World 10-Year Perspective for Gene Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2017, 2020 & 2027

Table 4: World Current & Future Analysis for Viral by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Viral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 and % CAGR

Table 6: World 10-Year Perspective for Viral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2017, 2020 & 2027

Table 7: World Current & Future Analysis for Non-Viral by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Non-Viral by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2017 through 2019 and % CAGR

Table 9: World 10-Year Perspective for Non-Viral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2017, 2020 & 2027

Table 10: World Current & Future Analysis for Oncological
Disorders by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 11: World Historic Review for Oncological Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2017 through 2019 and
% CAGR

Table 12: World 10-Year Perspective for Oncological Disorders
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2017, 2020 & 2027

Table 13: World Current & Future Analysis for Rare Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 14: World Historic Review for Rare Diseases by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2017 through 2019 and % CAGR

Table 15: World 10-Year Perspective for Rare Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2017, 2020 & 2027

Table 16: World Current & Future Analysis for Neurological
Disorders by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 17: World Historic Review for Neurological Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2017 through 2019 and
% CAGR

Table 18: World 10-Year Perspective for Neurological Disorders
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2017, 2020 & 2027

Table 19: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 20: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2017 through 2019 and
% CAGR

Table 21: World 10-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2017, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 22: USA Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 23: USA Historic Review for Gene Therapy by Vector Type -
Viral and Non-Viral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 24: USA 10-Year Perspective for Gene Therapy by Vector
Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 25: USA Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 26: USA Historic Review for Gene Therapy by Application -
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 27: USA 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

CANADA
Table 28: Canada Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 29: Canada Historic Review for Gene Therapy by Vector
Type - Viral and Non-Viral Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2017 through 2019 and %
CAGR

Table 30: Canada 10-Year Perspective for Gene Therapy by Vector
Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 31: Canada Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 32: Canada Historic Review for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2017 through 2019 and % CAGR

Table 33: Canada 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

JAPAN
Table 34: Japan Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 35: Japan Historic Review for Gene Therapy by Vector Type -
Viral and Non-Viral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 36: Japan 10-Year Perspective for Gene Therapy by Vector
Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 37: Japan Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 38: Japan Historic Review for Gene Therapy by Application -
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 39: Japan 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

CHINA
Table 40: China Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 41: China Historic Review for Gene Therapy by Vector Type -
Viral and Non-Viral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 42: China 10-Year Perspective for Gene Therapy by Vector
Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 43: China Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 44: China Historic Review for Gene Therapy by Application -
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 45: China 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

EUROPE
Table 46: Europe Current & Future Analysis for Gene Therapy by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 47: Europe Historic Review for Gene Therapy by Geographic
Region - France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2017 through 2019 and % CAGR

Table 48: Europe 10-Year Perspective for Gene Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2017, 2020 & 2027

Table 49: Europe Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: Europe Historic Review for Gene Therapy by Vector
Type - Viral and Non-Viral Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2017 through 2019 and %
CAGR

Table 51: Europe 10-Year Perspective for Gene Therapy by Vector
Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 52: Europe Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 53: Europe Historic Review for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2017 through 2019 and % CAGR

Table 54: Europe 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

FRANCE
Table 55: France Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 56: France Historic Review for Gene Therapy by Vector
Type - Viral and Non-Viral Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2017 through 2019 and %
CAGR

Table 57: France 10-Year Perspective for Gene Therapy by Vector
Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 58: France Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 59: France Historic Review for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2017 through 2019 and % CAGR

Table 60: France 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

GERMANY
Table 61: Germany Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 62: Germany Historic Review for Gene Therapy by Vector
Type - Viral and Non-Viral Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2017 through 2019 and %
CAGR

Table 63: Germany 10-Year Perspective for Gene Therapy by
Vector Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 64: Germany Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 65: Germany Historic Review for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2017 through 2019 and % CAGR

Table 66: Germany 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

ITALY
Table 67: Italy Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: Italy Historic Review for Gene Therapy by Vector Type -
Viral and Non-Viral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 69: Italy 10-Year Perspective for Gene Therapy by Vector
Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 70: Italy Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 71: Italy Historic Review for Gene Therapy by Application -
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 72: Italy 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

UNITED KINGDOM
Table 73: UK Current & Future Analysis for Gene Therapy by
Vector Type - Viral and Non-Viral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 74: UK Historic Review for Gene Therapy by Vector Type -
Viral and Non-Viral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 75: UK 10-Year Perspective for Gene Therapy by Vector
Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 76: UK Current & Future Analysis for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 77: UK Historic Review for Gene Therapy by Application -
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 and % CAGR

Table 78: UK 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

REST OF EUROPE
Table 79: Rest of Europe Current & Future Analysis for Gene
Therapy by Vector Type - Viral and Non-Viral - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 80: Rest of Europe Historic Review for Gene Therapy by
Vector Type - Viral and Non-Viral Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2017 through
2019 and % CAGR

Table 81: Rest of Europe 10-Year Perspective for Gene Therapy
by Vector Type - Percentage Breakdown of Value Sales for Viral
and Non-Viral for the Years 2017, 2020 & 2027

Table 82: Rest of Europe Current & Future Analysis for Gene
Therapy by Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 83: Rest of Europe Historic Review for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2017 through 2019 and % CAGR

Table 84: Rest of Europe 10-Year Perspective for Gene Therapy
by Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

ASIA-PACIFIC
Table 85: Asia-Pacific Current & Future Analysis for Gene
Therapy by Vector Type - Viral and Non-Viral - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 86: Asia-Pacific Historic Review for Gene Therapy by
Vector Type - Viral and Non-Viral Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2017 through
2019 and % CAGR

Table 87: Asia-Pacific 10-Year Perspective for Gene Therapy by
Vector Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 88: Asia-Pacific Current & Future Analysis for Gene
Therapy by Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 89: Asia-Pacific Historic Review for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2017 through 2019 and % CAGR

Table 90: Asia-Pacific 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

REST OF WORLD
Table 91: Rest of World Current & Future Analysis for Gene
Therapy by Vector Type - Viral and Non-Viral - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 92: Rest of World Historic Review for Gene Therapy by
Vector Type - Viral and Non-Viral Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2017 through
2019 and % CAGR

Table 93: Rest of World 10-Year Perspective for Gene Therapy by
Vector Type - Percentage Breakdown of Value Sales for Viral and
Non-Viral for the Years 2017, 2020 & 2027

Table 94: Rest of World Current & Future Analysis for Gene
Therapy by Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 95: Rest of World Historic Review for Gene Therapy by
Application - Oncological Disorders, Rare Diseases,
Neurological Disorders and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2017 through 2019 and % CAGR

Table 96: Rest of World 10-Year Perspective for Gene Therapy by
Application - Percentage Breakdown of Value Sales for
Oncological Disorders, Rare Diseases, Neurological Disorders
and Other Applications for the Years 2017, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 154
Read the full report: https://www.reportlinker.com/p05817594/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001